TFAP2E

Across TCGA pan-cancer cohorts, TFAP2E mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TFAP2E data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TFAP2E mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TFAP2E expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, COAD, and LUAD are the cancer types where TFAP2E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.829	0.259	<.001	50	view →
COAD	DFS	Median	All	0.932	1.000	.048	6	view →
LUAD	OS	Median	II,III,IV	0.871	1.000	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TFAP2E–PDAC (OS)

Open the PDAC breakdown →